Compare GILT & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GILT | AGMB |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | Israel | Belgium |
| Employees | 1159 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.3M | 576.2M |
| IPO Year | 1997 | 2024 |
| Metric | GILT | AGMB |
|---|---|---|
| Price | $7.69 | $7.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $19.20 | ★ $37.67 |
| AVG Volume (30 Days) | ★ 923.6K | 127.5K |
| Earning Date | 11-10-2026 | 11-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.44 | N/A |
| Revenue Next Year | $11.62 | N/A |
| P/E Ratio | $42.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.23 | $7.45 |
| 52 Week High | $20.99 | $17.82 |
| Indicator | GILT | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 28.40 |
| Support Level | $7.23 | N/A |
| Resistance Level | $10.39 | $9.55 |
| Average True Range (ATR) | 0.31 | 0.70 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 38.96 | 26.68 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.